IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVA

Core Viewpoint - Iovance Biotherapeutics, Inc. is facing a securities class action lawsuit due to alleged failure to disclose material information during the specified class period, leading to significant financial losses for investors [3]. Group 1: Lawsuit Details - Investors who purchased Iovance securities between May 9, 2024, and May 8, 2025, have until July 15, 2025, to file lead plaintiff applications [1]. - The lawsuit is pending in the United States District Court for the Northern District of California, under the case name Farberov v. Iovance Biotherapeutics, Inc., et al., Case No. 25-cv-4199 [5]. Group 2: Financial Performance - Iovance reported a total product revenue of $49.3 million for Q1 2025, a decline from $73.7 million in the previous quarter [4]. - The company has revised its full fiscal year 2025 total product revenue guidance from a range of $450 million - $475 million to $250 million - $300 million, reflecting recent launch dynamics [4]. - Following the announcement of these financial results, Iovance's share price fell by 44.8%, from $1.42 to $1.75 per share on May 9, 2025, with unusually heavy trading volume [4]. Group 3: Legal Representation - Kahn Swick & Foti, LLC, a prominent securities litigation law firm, is representing investors in this case, with a history of recovering investment losses due to corporate fraud [5].